Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Int J Radiat Oncol Biol Phys ; 97(2): 362-371, 2017 02 01.
Article in English | MEDLINE | ID: mdl-28011047

ABSTRACT

PURPOSE: For inoperable stage I (T1-T2N0) small cell lung cancer (SCLC), national guidelines recommend chemotherapy with or without conventionally fractionated radiation therapy. The present multi-institutional cohort study investigated the role of stereotactic ablative radiation therapy (SABR) for this population. METHODS AND MATERIALS: The clinical and treatment characteristics, toxicities, outcomes, and patterns of failure were assessed in patients with histologically confirmed stage T1-T2N0M0 SCLC. Kaplan-Meier analysis was used to evaluate the survival outcomes. Univariate and multivariate analyses identified predictors of outcomes. RESULTS: From 24 institutions, 76 lesions were treated in 74 patients (median follow-up 18 months). The median age and tumor size was 72 years and 2.5 cm, respectively. Chemotherapy and prophylactic cranial irradiation were delivered in 56% and 23% of cases, respectively. The median SABR dose and fractionation was 50 Gy and 5 fractions. The 1- and 3-year local control rate was 97.4% and 96.1%, respectively. The median disease-free survival (DFS) duration was 49.7 months. The DFS rate was 58.3% and 53.2% at 1 and 3 years, respectively. The median, 1-year, and 3-year disease-specific survival was 52.3 months, 84.5%, and 64.4%, respectively. The median, 1-year, and 3-year overall survival (OS) was 17.8 months, 69.9%, and 34.0% respectively. Patients receiving chemotherapy experienced an increased median DFS (61.3 vs 9.0 months; P=.02) and OS (31.4 vs 14.3 months; P=.02). The receipt of chemotherapy independently predicted better outcomes for DFS/OS on multivariate analysis (P=.01). Toxicities were uncommon; 5.2% experienced grade ≥2 pneumonitis. Post-treatment failure was most commonly distant (45.8% of recurrence), followed by nodal (25.0%) and "elsewhere lung" (20.8%). The median time to each was 5 to 7 months. CONCLUSIONS: From the findings of the largest report of SABR for stage T1-T2N0 SCLC to date, SABR (≥50 Gy) with chemotherapy should be considered a standard option.


Subject(s)
Lung Neoplasms/radiotherapy , Radiosurgery/methods , Small Cell Lung Carcinoma/radiotherapy , Adult , Aged , Aged, 80 and over , Analysis of Variance , Antineoplastic Agents/therapeutic use , Combined Modality Therapy/methods , Cranial Irradiation/statistics & numerical data , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Lung Neoplasms/drug therapy , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Male , Middle Aged , Proportional Hazards Models , Radiation Pneumonitis/etiology , Radiosurgery/adverse effects , Radiotherapy Dosage , Small Cell Lung Carcinoma/drug therapy , Small Cell Lung Carcinoma/mortality , Small Cell Lung Carcinoma/pathology , Treatment Outcome , Tumor Burden
2.
Int J Radiat Oncol Biol Phys ; 92(2): 220-7, 2015 Jun 01.
Article in English | MEDLINE | ID: mdl-25841622

ABSTRACT

PURPOSE AND OBJECTIVES: This report presents the analysis of the RTOG 0537 multicenter randomized study that compared acupuncture-like transcutaneous stimulation (ALTENS) with pilocarpine (PC) for relieving radiation-induced xerostomia. METHODS AND MATERIALS: Eligible patients were randomized to twice-weekly 20-minute ALTENS sessions for 24 sessions during 12 weeks or PC (5 mg 3 times daily for 12 weeks). The primary endpoint was the change in the University of Michigan Xerostomia-Related Quality of Life Scale (XeQOLS) scores from baseline to 9 months from randomization (MFR). Secondary endpoints included basal and citric acid primed whole salivary production (WSP), ratios of positive responders (defined as patients with ≥20% reduction in overall radiation-induced xerostomia symptom burden), and the presence of adverse events based on the Common Terminology Criteria for Adverse Events version 3. An intention-to-treat analysis was conducted. RESULTS: One hundred forty-eight patients were randomized. Only 96 patients completed the required XeQOLS and were evaluable at 9 MFR (representing merely 68.6% statistical power). Seventy-six patients were evaluable at 15 MFR. The median change in the overall XeQOLS in ALTENS and PC groups at 9 and 15 MFR were -0.53 and -0.27 (P=.45) and -0.6 and -0.47 (P=.21). The corresponding percentages of positive responders were 81% and 72% (P=.34) and 83% and 63% (P=.04). Changes in WSP were not significantly different between the groups. Grade 3 or less adverse events, mostly consisting of grade 1, developed in 20.8% of patients in the ALTENS group and in 61.6% of the PC group. CONCLUSIONS: The observed effect size was smaller than hypothesized, and statistical power was limited because only 96 of the recruited 148 patients were evaluable. The primary endpoint-the change in radiation-induced xerostomia symptom burden at 9 MFR-was not significantly different between the ALTENS and PC groups. There was significantly less toxicity in patients receiving ALTENS.


Subject(s)
Pilocarpine/therapeutic use , Transcutaneous Electric Nerve Stimulation/methods , Xerostomia/therapy , Acupuncture Therapy , Adult , Aged , Drug Administration Schedule , Female , Humans , Intention to Treat Analysis , Male , Middle Aged , Quality of Life , Radiotherapy/adverse effects , Salivation , Time Factors , Xerostomia/etiology
3.
Cancer Inform ; 13(Suppl 1): 49-57, 2014.
Article in English | MEDLINE | ID: mdl-25392683

ABSTRACT

This work examines the feasibility and implementation of information service-orientated architecture (ISOA) on an emergent literature domain of human papillomavirus, head and neck cancer, and imaging. From this work, we examine the impact of cancer informatics and generate a full set of summarizing clinical pearls. Additionally, we describe how such an ISOA creates potential benefits in informatics education, enhancing utility for creating enduring digital content in this clinical domain.

4.
J Okla State Med Assoc ; 100(12): 469-72, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18251237

ABSTRACT

OBJECTIVE: To compare standing PA flexed (SPAF) knee radiographs of the knees with standing full-extension AP(SAP) radiographs for demonstration of narrowing of the articular cartilage of the knee joint and the presence and size of osteophytes and to determine if sclerosis is a predictor of the severity of joint space narrowing. DESIGN: 220 knees in 110 consecutive patients visiting the orthopaedic clinic with knee pain and having both SPAF radiographs and SAP radiographs at the same visit were evaluated by a musculoskeletal radiologist for cartilage narrowing in the knee joint using a scale 0-3 with 0= normal and 3= bone on bone. Osteophytes were also graded 0-3 and sclerosis as present or absent. PATIENTS: The subjects were patients of one of the authors (C.A.J) who ordered both types of radiographs on most of his patients. RESULTS: In 47% of knees the SPAF radiograph showed narrowing more severe than the SAP radiograph. In 5% the SAP view showed narrowing more severe than the SPAF view. In the medial compartment the SPAF view showed significantly larger osteophytes than the SAP view. The osteophyte size difference was not significant in the lateral compartment. If sclerosis was present on the AP view, there was a greater than 80% chance that the SPAF view would show greater narrowing. CONCLUSION: The SPAF radiograph frequently shows more cartilage narrowing in the knee joint than does the SAP view. It is valuable for routine use or when the clinical severity of arthritis in the knee joint seems to be greater than that demonstrated on the AP standing view. Sclerosis on the SAP view makes it especially likely that the SPAF view will show greater cartilage narrowing.


Subject(s)
Cartilage, Articular/diagnostic imaging , Joint Diseases/diagnostic imaging , Knee Joint/diagnostic imaging , Posture , Arthralgia/diagnostic imaging , Humans , Osteophyte/diagnostic imaging , Pilot Projects , Radiography , Sclerosis/diagnostic imaging , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL
...